IP Library Granted Patent US 7,727,545
Granted Patent B2
US 7,727,545 · App. 11/359,665 · Granted Jun 1, 2010

Polymeric fluorinated dioxole and medical devices comprising same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,727,545
App. No.
11/359,665
Granted
Jun 1, 2010
Kind
B2
Abstract

A polymeric material having improved gas permeability comprises units of fluorinated dioxole. The polymeric material may further comprise units of a hydrophobic monomer, a hydrophilic monomer, or combinations thereof. Such a polymeric material is desirably used to produce medical devices, such as ophthalmic devices that provide increased comfort to a user.

Claims (10)

1. A medical device comprising a polymeric composition that comprises units of fluorinated dioxole that has a formula selected from the group consisting of

and combinations thereof, wherein X is independently selected from the group consisting of hydrogen, fluorine, and R 1 , R 2 are independently selected from the group consisting of substituted and unsubstituted lower alkyl groups, substituted and unsubstituted alkyloxy groups, substituted and unsubstituted aromatic and heteroaromatic groups having 6-36 carbon atoms in a ring system, substituted and unsubstituted cyclic and heterocyclic groups having 6-36 carbon atoms in a ring system, and combinations thereof; and at least one of the groups R 1 , R 2 , and X comprises a fluorinated group and at least one of R 1 , R 2 comprises a substituted or unsubstituted aromatic group having 6-36 carbon atoms in a ring system.

2. The medical device of claim 1 , wherein X is fluorine.

3. The medical device of claim 1 , wherein the polymeric composition comprises units of fluorinated dioxole having Formula I, II, or combinations thereof.

4. The medical device of claim 1 , wherein the polymeric composition comprises units of fluorinated dioxole having Formula III.

5. The medical device of claim 1 , wherein the polymeric composition comprises units of an additional monomer selected from the group consisting of hydrophobic monomers, hydrophilic monomers, combinations thereof, and mixtures thereof.

6. The medical device of claim 1 , wherein the polymeric composition comprises units of a vinyl-terminated polysiloxane, wherein the polysiloxane comprises a side group that comprises an aromatic group having 6-36 carbon atoms in a ring system.

7. The medical device of claim 6 , wherein the polysiloxane comprises a side group that comprises a fluorinated lower alkyl group.

8. The medical device of claim 6 , wherein the polymeric composition comprises units of a hydrophilic monomer.

9. The medical device of claim 1 , wherein the medical device is a contact lens, an intraocular lens, a corneal inlay, a corneal ring, or a keratoprothesis.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Aug 5, 2010
From: BAUSCH & LOMB INCORPORATED
To: CREDIT SUISSE AG, AS ADMINISTRATIVE AGENT
Reel/Frame 024785/0948 →
SECURITY AGREEMENT Recorded Nov 16, 2007
From: BAUSCH & LOMB INCORPORATED; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; IOLAB CORPORATION; RHC HOLDINGS, INC.; WP PRISM, INC.
To: CREDIT SUISSE
Reel/Frame 020122/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2006
From: SALAMONE, JOSEPH C.; SCHORZMAN, DEREK A.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 017581/0824 →